Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II crossover trial of glycopyrronium bromide in children with asthma
2021-004972-32Phase 2Active
- Sponsor
- Novartis
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in asthma (6 arms), sponsored by Novartis. Primary endpoint: Change from baseline in trough forced expiratory volume in one second at week 2 of each treatment period. Started Apr 2022; status: active.
02
Drugs
glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on 2021-004972-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004972-32.